login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PALVELLA THERAPEUTICS INC (PVLA) Stock News
USA
- NASDAQ:PVLA -
US6979471090
-
Common Stock
93.99
USD
+11.05 (+13.32%)
Last: 11/19/2025, 2:58:31 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PVLA Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Chartmill
Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones
8 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
8 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
8 days ago - By: Benzinga
- Mentions:
NXGL
SE
UPXI
SFL
...
Earnings Scheduled For November 11, 2025
13 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
13 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
14 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
14 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
15 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
15 days ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
a month ago - By: Palvella Therapeutics Inc.
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
a month ago - By: Palvella Therapeutics Inc.
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
2 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
2 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
2 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
2 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
2 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
2 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
3 months ago - By: Palvella Therapeutics Inc.
- Mentions:
ARQT
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
3 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
3 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
3 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
3 months ago - By: The Motley Fool
Palvella Posts Cash Gain and Trial Wins
3 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
3 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
3 months ago - By: Benzinga
- Mentions:
BTCM
DE
TIC
DFLI
...
Earnings Scheduled For August 14, 2025
3 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
4 months ago - By: Yahoo Finance
- Mentions:
WFC
UBS
MNDY
CACI
...
Snap downgraded, Leidos upgraded: Wall Street's top analyst calls
4 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
4 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
4 months ago - By: Yahoo Finance
Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin
5 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
5 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
5 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
5 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
5 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
5 months ago - By: Palvella Therapeutics Inc.
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
Please enable JavaScript to continue using this application.